The United Kingdom and the United States have reached a important bilateral deal that will ensure zero duties on UK pharmaceutical exports entering the American market.
Key Provisions of the Deal
As part of the deal, the UK has agreed to increase spending on pharmaceuticals through the National Health Service (NHS). This pledge secures that import taxes on these crucial goods will stay at zero for a duration of 36 months.
This development comes after recent threats to hike duties on branded drug imports, with potential rates mentioned reaching 100%.
"This arrangement with the Britain strengthens the global environment for innovative medicines and brings long-overdue equity to transatlantic pharmaceutical trade," a release noted.
Commercial Significance
Pharmaceuticals constitute one of the UK's largest exports to the America, which is easily the largest destination for major British pharmaceutical firms.
Statistics indicate that in the 12 months leading up to September, the UK exported medicines totaling over eleven billion pounds to the US. This value represented 17.4% of total UK exports in that period.
"This guarantee safeguards employment, increases capital expenditure and paves the way for the UK to become a worldwide center for biotech and pharma," a minister remarked.
Detailed UK Commitments
The deal includes several specific pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the price threshold at which it considers new therapies to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a target to increase total public funding on drugs from 0.3 percent of GDP to 0.6% over the following ten-year period.
- Refund Ceiling: The percentage drug companies must return to the NHS to prevent overspending will be restricted at fifteen percent. Previously, repayments topped 20%.
Broader Context
This agreement follows a ongoing tension between the pharmaceutical industry and the British authorities over spending levels and regulatory access.
The disagreement were exacerbated by claims that US customers were paying several times more for the equivalent treatments than people in the Britain and the EU.
Over the last 18 months, several significant drug company projects in the UK have been halted or abandoned, while multi-billion-dollar expansions have been pledged toward projects in the United States.
The Science Minister publicly accepted that the NHS needed to increase expenditure on drugs, noting that its spending on drugs had shrunk as a percentage of its total funding over the last ten years.
